Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Abstract Background Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies. Methods In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation’s largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders). Results Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes. Conclusions In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.

Ahnalee M. Brincks | J. M. Crawford | Stefani N. Thomas | P. Gregersen | J. Skarbinski | M. Lipsitch | R. Baric | E. Kenah | F. Hirsch | J. Crawford | S. Wallet | R. Ahmed | J. LaBaer | W. Britt | S. Klein | B. Diamond | L. Richardson | G. Alter | R. Sékaly | E. Taioli | S. Boppana | D. Corley | B. Amick | Todd Lucas | V. Simon | M. Wolfgang | R. Fan | S. Parekh | D. Weiskopf | W. Nembhard | L. Kushi | L. Bartelt | N. Mantis | I. Sanz | S. Halene | F. Krammer | A. Moormann | D. Granger | D. Barouch | Dongjoo Kim | A. Karger | C. Forconi | M. Suthar | S. Granger | J. Schieffelin | D. Zidar | A. Brincks | Ann Scheck McAlearney | A. Panchal | K. Reckamp | B. Thyagarajan | M. Rana | J. Roback | D. Furr-Holden | David A. Zidar | K. Boehme | N. Bowman | J. Brien | A. Neish | G. Melmed | C. Heaney | Jessica T. Lin | David A Zidar | Jennifer VanOudenhove | S. Forrester | Swetha Pinninti | J. Figueiredo | S. Pati | A. Karaba | L. Schifanella | J. Kennedy | A. Wajnberg | R. Hagan | A. Espino | Giulia Biancon | N. Zohoori | A. Markmann | C. Sariol | C. Forrest | N. Jones | J. Braun | Ruofei Du | Soledad A Fernandez | Misty Latting | A. Cox | R. Binder | Kent D Key | A. Merchant | N. Merin | L. Finster | Dermot McGovern | Alba Gifoni | William Hanege | E. Yvonne Lewis | Jennifer Batista | Jens Wrammerr | Serre Yu Wong | R. McBride | Maria Knight Lapinski | Marcos Lopez | M. Dhodapkar | Soledad A. Fernandez | Russell McBride | Russell B McBride | G. Biancon | S. Klein | Sarah N. Forrester | Nicole M. Jones | Raquel A. Binder | F. Hirsch | Andrea L. Cox

[1]  J. Blankson,et al.  Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients , 2022, Transplantation.

[2]  N. Sharma,et al.  SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home order , 2021, Journal of Clinical Virology Plus.

[3]  C. Henschke,et al.  Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation , 2021, Journal of Thoracic Oncology.

[4]  J. Casanova,et al.  The intersection of COVID-19 and autoimmunity. , 2021, The Journal of clinical investigation.

[5]  R. Baric,et al.  Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines , 2021, The New England journal of medicine.

[6]  D. Barouch,et al.  COVID-19 Vaccines: Adenoviral Vectors. , 2021, Annual review of medicine.

[7]  T. Ndung’u,et al.  HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave , 2021, eLife.

[8]  G. Lozanski,et al.  Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H , 2021, mBio.

[9]  A. Mita,et al.  SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment , 2021, Annals of Oncology.

[10]  S. Jagannath,et al.  Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma , 2021, Cancer Cell.

[11]  K. Crandall,et al.  Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data , 2021, The Lancet HIV.

[12]  P. Kelleher,et al.  Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients , 2021, The Lancet.

[13]  Katie M. Campbell,et al.  How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. , 2021, Blood cancer discovery.

[14]  S. Zeger,et al.  Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19 , 2021, Open forum infectious diseases.

[15]  J. Blankson,et al.  A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients , 2021, American Journal of Transplantation.

[16]  S. Targan,et al.  Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease , 2021, Gastroenterology.

[17]  O. Laeyendecker,et al.  The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. Schuitemaker,et al.  Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination , 2021, The New England journal of medicine.

[19]  S. Jagannath,et al.  Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma , 2021, Cancer Cell.

[20]  D. Segev,et al.  Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients , 2021, Transplantation.

[21]  H. Schuitemaker,et al.  Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques , 2021, Nature.

[22]  P. Klenerman,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.

[23]  S. Klein,et al.  Beyond a Zero-Sum Game: How Does the Impact of COVID-19 Vary by Gender? , 2021, Frontiers in Sociology.

[24]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[25]  M. Juan,et al.  Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients , 2021, American Journal of Transplantation.

[26]  D. McGovern,et al.  Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease , 2021, The American journal of gastroenterology.

[27]  J. Izopet,et al.  Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants , 2021, Annals of Internal Medicine.

[28]  S. Klein,et al.  Sex-biased clinical presentation and outcomes from COVID-19 , 2021, Clinical Microbiology and Infection.

[29]  A. Satin,et al.  Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection , 2021, American Journal of Obstetrics and Gynecology.

[30]  R. Bhopal,et al.  Children and young people remain at low risk of COVID-19 mortality , 2021, The Lancet Child & Adolescent Health.

[31]  M. Oster,et al.  Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study , 2021, The Lancet Child & Adolescent Health.

[32]  S. Klein,et al.  COVID-19: use intersectional analyses to close gaps in outcomes and vaccination , 2021, Nature.

[33]  W. Britt,et al.  Virological Characteristics of Hospitalized Children With SARS-CoV-2 Infection , 2021, Pediatrics.

[34]  M. Dubinsky,et al.  SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting , 2021, Gut.

[35]  J. Margolick,et al.  Aging in COVID-19: Vulnerability, immunity and intervention , 2020, Ageing Research Reviews.

[36]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[37]  Elizabeth B White,et al.  Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[38]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[39]  I. Sanz,et al.  Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19 , 2020 .

[40]  D. Morales,et al.  Racial/Ethnic Disparities in Household Food Insecurity During the COVID-19 Pandemic: a Nationally Representative Study , 2020, Journal of Racial and Ethnic Health Disparities.

[41]  G. Lozanski,et al.  Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors , 2020, JCI insight.

[42]  William T. Hu,et al.  Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 , 2020, Nature Immunology.

[43]  M. Jorge Cardoso,et al.  Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study , 2020, The Lancet Public Health.

[44]  J. M. Crawford,et al.  Rapid Emergence of SARS-CoV-2 in the Greater New York Metropolitan Area: Geolocation, Demographics, Positivity Rates, and Hospitalization for 46 793 Persons Tested by Northwell Health , 2020, Clinical Infectious Diseases.

[45]  Harnish Mukesh Naik,et al.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population , 2020, medRxiv.

[46]  P. Sullivan,et al.  COVID-19 and the US response: accelerating health inequities , 2020, BMJ Evidence-Based Medicine.

[47]  Asher Mullard COVID-19 vaccine development pipeline gears up , 2020, The Lancet.

[48]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[49]  J. Qiao What are the risks of COVID-19 infection in pregnant women? , 2020, The Lancet.

[50]  Barry Smith,et al.  ImmPort, toward repurposing of open access immunological assay data for translational and clinical research , 2018, Scientific Data.

[51]  Oacar Handlin,et al.  Loss of Will , 2017 .

[52]  S. Klein,et al.  Sex differences in immune responses , 2016, Nature Reviews Immunology.

[53]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[54]  S. Parinitha,et al.  Haematological changes in HIV infection with correlation to CD4 cell count. , 2012, The Australasian medical journal.

[55]  G. Trinchieri,et al.  Persistent Decreases in Blood Plasmacytoid Dendritic Cell Number and Function Despite Effective Highly Active Antiretroviral Therapy and Increased Blood Myeloid Dendritic Cells in HIV-Infected Individuals1 , 2002, The Journal of Immunology.

[56]  B. Gazzard,et al.  Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. , 2001, Blood.